Organ transplantation requires the use of immunosuppressive drugs to prevent rejection of the transplanted organ, substantially limiting its benefit and augmenting its risk. Unfortunately, all regimens, regardless of the agents used, are incompletely and transiently effective, and induce some degree of immune incompetence for life. Since its discovery, costimulation blockade (CoB) has been suggested as a means of attaining indefinite, well-tolerated, antigen-specific prophylaxis from allograft rejection. An exemplary approach is blockade of the CD28/B7 pathway. Although exceedingly effective in some rodent models, CD28/B7 blockade is not alone sufficient to prevent rejection in primates, including humans. Several mechanisms of CoB- resistant rejection have been suggested, many related to the relative presence of activated alloreactive memory-phenotype T cells. We now have found that treatment with the CD2 specific fusion protein LFA-3-Ig (alefacept) synergizes with the CD28/B7-targeted fusion protein abatacept successfully preventing renal allograft rejection in primates. We hypothesize that alefacept specifically targets many of the factors fostering CoB resistance, including heterologous alloreactive T cell memory, while avoiding interference with peripheral mechanisms that serve to foster CoB-mediated allograft acceptance, including T cell regulation and donor antigen-specific T cell elimination. We therefore propose to investigate the mechanisms by which alefacept improved CoB and use this information to optimize its use, developing a clinically applicable therapy to prevent allograft rejection without the use of calcineurin inhibitors, steroids, or gross T cell depletion. In developing the regimen, we will specifically test alefacept's ability to eliminate pre-existing and induce memory T cells, evaluating the absolute and relative effects of alefacept on allospecific and memory T cells, and viral specific memory T cells. Throughout the study, we will determine the degree to which this regimen's influence on alloimmunity alters protective viral immunity. Based on preliminary evidence suggesting a salutary role for donor specific antigen infusion, we also will determine the degree to which antigen exposure at transplant improves the durability of the effect of this regimen, augmenting the allospecific effect without altering its effect on protective immunity. As this regimen uses agents that are approved for clinical use, this will provide data in support of an immediately translatable strategy to prevent rejection in humans, and establish generalizable knowledge regarding the role of T cell memory in thwarting CoB-based immune modulation.

Public Health Relevance

Immunosuppressive drugs are required to prevent organ transplant rejection;unfortunately, an optimally effective, non-toxic drug regimen is yet to be developed. Costimulation blockade (CoB) has been shown to prevent rejection in rodents, but is far less effective in primates;however, we have developed a regimen pairing CoB with a fusion protein, alefacept, and have shown that it prevents renal allograft rejection in primates, hypothetically due to alefacept's effects countering CoB-resistant mechanisms of rejection. We propose to determine the mechanisms involved in alefacept's action focusing on its effects on allo- and viral-specific immunity, and in doing so develop this regimen into a well-tolerated, clinically applicable, and mechanistically sound therapy to prevent allograft rejection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI079223-02
Application #
7795811
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Kraemer, Kristy A
Project Start
2009-03-27
Project End
2013-02-28
Budget Start
2010-03-01
Budget End
2011-02-28
Support Year
2
Fiscal Year
2010
Total Cost
$613,352
Indirect Cost
Name
Emory University
Department
Surgery
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Song, M; Mulvihill, M S; Williams, K D et al. (2018) Fatal SV40-associated pneumonia and nephropathy following renal allotransplantation in rhesus macaque. J Med Primatol 47:81-84
Samy, K P; Anderson, D J; Lo, D J et al. (2017) Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model. Am J Transplant 17:1193-1203
Anderson, D J; Lo, D J; Leopardi, F et al. (2016) Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection. Am J Transplant 16:1456-64
Singh, K; Stempora, L; Harvey, R D et al. (2014) Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant 14:2691-703
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Lowe, M C; Badell, I R; Turner, A P et al. (2013) Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant 13:312-9
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8
Page, A; Srinivasan, S; Singh, K et al. (2012) CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant 12:115-25
Ramakrishnan, S K; Page, A; Farris 3rd, A B et al. (2012) Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant 12:1755-64
Singh, K; Kozyr, N; Stempora, L et al. (2012) Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 12:1441-57

Showing the most recent 10 out of 14 publications